New study highlights a potential biomarker (CACNA2D1) and a novel therapeutic approach (SEAD1) for cognitive symptoms in schizophrenia. Findings show promise in restoring brain circuit activity in preclinical models. 🔗 news.feinberg.northwestern.edu/2026/03/19/s...

Schizophrenia Study Finds New Biomarker, Drug Candidate to Treat Cognitive Symptoms - News Center

A new Northwestern study in humans and mice has discovered a novel biomarker of schizophrenia that could also serve as a new drug candidate to treat the cognitive symptoms of the disorder.

news.feinberg.northwestern.edu

If you missed the webinar held on December 2, 2025, you can watch the recording here: www.youtube.com/watch?v=LPlS...

Autism Across the Spectrum: From Understanding the Brain to Developing New Treatments 12.2.2025

YouTube video by Northwestern University Medical Alumni Association

youtube.com

Congrats to Marc Forrest, Ph.D., on receiving a 2025 BBRF Young Investigator Grant for innovative mental health research. More info: bbrfoundation.org/content/brai...

Euan Parnell (Penzes Lab) & Melanie J. Grubisha (Univ. of Pittsburgh) published “Oligodendrocyte myelin glycoprotein impairs dendritic arbors via schizophrenia risk gene Trio.” OMGp shapes neurons via a schizophrenia risk gene, offering new insight. www.sciencedirect.com/science/arti...

Congrats to Jessica Christiansen from the Penzes Lab 🎉 Her work on TRIO and KALRN earned 2nd place in Basic Science at Feinberg Pavilion. She’s helping uncover how gene changes impact autism, schizophrenia, and intellectual disability.

Great to see Colleen Zaccard’s AAIC presentation on tunneling nanotubes (TNT) spotlighted by Alzforum. Her research shows how inflammatory conditions boost TNT growth and shape neuron–microglia communication in Alzheimer’s disease. Read more: www.alzforum.org/news/confere...

Dr. Peter Penzes presented “Synaptic Sheddome in Schizophrenia: From Mechanisms to Therapies” at the ISN–ASN joint meeting in New York, sharing new insights that connect fundamental mechanisms to potential therapies

A CAN community member attended #AAIC25 in Toronto, where experts shared: new blood-based biomarker guidelines, promising Lecanemab & Donanemab results, and lifestyle insights from the U.S. POINTER trial. More here: www.feinberg.northwestern.edu/sites/autism...